ANTIMICROBIAL RESISTANCE DIAGNOSTICS MARKET, STRATEGIES & TRENDS BY PATHOGEN AND TECHNOLOGY WITH EXECUTIVE GUIDES AND CUSTOMIZATION 2018 to 2023
Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. We have looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections, can be diagnosed. We have identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts. We profile 20 companies, large and small, working in this area.
Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
- 1. Introduction and Market Definition
- 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
- 1.2 Defining the Opportunity
- 1.2.1 Revenue Market Size
- 1.3 Methods and Sources
- 1.3.1 Authors
- 1.3.2 Sources
- 1.4 U.S. Antibiotic Markets - Perspective
- 1.4.1 U.S. Outpatient Use of Antibiotics
- 1.4.2 U.S. Pharmaceutical Spending
- 2. Overview of a Dynamic Market
- 2.1 Market Players – Roles & Impacts
- 2.1.1 Drug manufacturers - Larger/pharmaceutical
- 2.1.2 Drug manufacturers - Generic
- 2.1.3 Contract Research and Manufacturing
- 2.1.4 In Vitro Diagnostics Industry
- 2.1.5 Drug Marketing Companies
- 2.1.6 Biotechnology Companies
- 2.1.7 Regulatory Bodies
- 2.2 Understanding Antimicrobial Resistance
- 2.2.1 What is Antimicrobial Resistance (AMR)
2.2.2 Bacteria and Other Microbes 2.2.3 The History of Antibiotics 2.2.4 The Role of Animal Husbandry 2.2.5 The Implications of Horizontal Transfer 2.2.6 The Threat of AMR 2.3 The Changing Road to New Antibiotics & Technologies 2.4 The Key Role of Diagnostics in AMR 3. The Market Opportunity of AMR3.1 The Key Large Market Opportunities in AMR 3.1.1 Streptococcus Pneumoniae (DRSP) 3.1.2 Campylobacter (DRC) 3.1.3 Clostridium Difficile (CD) 3.1.4 Staphylococcus aureus (MRSA) 3.1.5 Neisseria gonorrhoeae (DRNG) 3.1.6 Salmonella (DRNTS) 3.2 Diagnostic Technology Development Opportunities 3.2.1 What’s Wrong with Microbiology 3.2.2 The Features Battleground of Infectious Disease Diagnostics 3.2.3 Multiplex vs. POC/Rapid 3.2.4 The Miracle of Genetics 3.2.5 From Multiple Pathogens to All Pathogens – The Next Next Generation3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing. 3.2.7 Markers of Resistance. 3.2.8 What Happens to the Microbiology Lab? 3.4. Antibiotic Resistance Recent Developments 3.4.1 Recent Developments – Importance and How to Use This Section 3.4.2 Importance of These Developments 3.4.3 How to Use This Section 3.4.4 Quick identification of multidrug-resistant pathogens 3.4.5 Metagenomics Enables Researchers to Uncover Drug Resistance Genes 3.4.6 Rapid detection of multi-drug-resistant bacteria3.4.7 Improved Diagnostics Fail to Halt the Rise of Tuberculosis 3.4.8 High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges 3.4.9 New solution for diagnosing antibiotic-resistant bacteria 3.4.10 MALDI-TOF – Results in Minutes not Days. 3.4.11 CRISPR Tool Used to Uncover Infections 3.4.12 Automated Blood Tests Startup MeMed Raises Funds, Wins Grant 3.4.13 BD, Check-Points Receive CE Mark for Resistant Organism Screening Test 3.4.14 LiDia® BSI Detects Pathogens and Antimicrobial Resistance 3.4.15 New tool can Track Resistant Malaria 3.4.16 Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs 3.4.17 Longitude Funds for POC Tests 3.4.18 New test can identify dangerous bacteria with resistance to last-resort antibiotic 3.4.19 bioMérieux receives FDA clearance for expanded pathogen identification capability 3.4.20 OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests 3.4.21 Hospital Plumbing Harbors Antibiotic Resistant Bacteria 3.4.22 Acquisition Strategy Fills Out Roche's Diagnostic Pipeline 3.4.23 Curetis Gets Singapore Approval for Pneumonia Test 3.4.24 PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx 3.4.25 Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies 3.4.26 Fusion Genomics Developing All Pathogens Diagnostic. 4. Key Biotechnology Companies and Their Technology 4.1 Diagnostics 4.1.1 1928 Diagnostics 4.1.2 Sense Biodetection. 4.1.3 Fusion Genomics. 4.1.4 Day Zero Diagnostics. 4.1.5 Inflammatix 4.1.6 Hutman Diagnostics 4.1.8 bioMérieux Diagnostics 4.1.9 Curetis N.V. / Curetis GmbH 4.1.10 Great Basin Corporation 4.1.11 Becton, Dickinson and Company 4.1.12 Roche Diagnostics 4.1.13 Cepheid (now Danaher) 4.1.14 Atlas Genetics 4.1.14 Accelerate Diagnostics 4.1.15 Seimens 4.1.16 Abbott Diagnostics 4.1.17 Thermo Fisher 4.1.18 Bio - Rad 4.1.19 Sysmex 4.1.20 Ortho Clinical 5. The Global Market 5.1 Global Market by Country 6. Global Market by Pathogens 6.1 Global Market by Pathogens6.2 DRSP 6.3 DRC 6.4 CD 6.5 MRSA 6.5 DRNG 6.6 DRNTS 7. AMR Diagnostics by Technology 7.1 Global Market by Technology 7.2 Bacterial Culture 7.3 Immunoassay 7.4 Polymerase Chain Reaction 7.5 Genetic Sequencing 7.6 Mass Spectrometer 7.7 Rapid, POC and Other 8. Vision of the Future of AMR Diagnostics Table of TablesTable 1 USA - Outpatient Use of Antibiotics by Class Table 2 USA - Outpatient Use of Antibiotics Top 5 Table 3 Market Players by Type Table 4 Known Human Pathogenic Diseases Table 5 The Key Market Opportunities Table 6 - Market Potential DRSP Diagnostic Table 7 - Market Potential DRC Diagnostic Table 8 - Market Potential CD Diagnostic Table 9 - Market Potential CD Diagnostic Table 10 Market Potential DRNG Diagnostic Table 11 Market Potential DRNTS Diagnostic Table 12 – Key AMR Diagnostics Issues Table 13 The Global AMR Diagnostic Market by Country Table 14 Global Market by Pathogen Table 15 DRSP Diagnostics by Country Table 16 DRC Diagnostics by Country Table 17 CD Diagnostics by Country Table 18 MRSA Diagnostics by Country Table 19 DRNG Diagnostics by Country Table 20 DRNTS Diagnostics by Country Table 21 Global Market by Technology Table 22 Culture Diagnostics by Country Table 23 Immunoassay Diagnostics by Country Table 24 PCR Diagnostics by Country Table 25 NGS Diagnostics by Country Table 26 MS Diagnostics by Country Table 27 Rapid, POC and Other Diagnostics by Country Table of FiguresFigure 1 Pharmaceutical Spending History by Country Figure 2 AMR and Antibiotic Introduction Figure 3 The Death Toll of AMR Figure 4 AMR Diagnostics - Key CountriesFigure 5 Chart of Share Change by Pathogen Figure 6 Chart – DRSP Diagnostics by Country Figure 7 Chart – DRC Diagnostics by Country Figure 8 Chart – CD Diagnostics by Country Figure 9 Chart - Infectious Disease Immunoassay by Country Figure 10 Chart – DRNG Diagnostics by Country Figure 11 Chart – DRNTS Diagnostics by CountryFigure 12 Chart of Growth by TechnologyFigure 13 Chart - Technology Change in Planning Period Figure 14 Chart – Bacterial Culture by Country Figure 15 Chart – Immunoassay Diagnostics by Country Figure 16 Chart – PCR Diagnostics by Country Figure 17 Chart – NGS Diagnostics by CountryFigure 18 Chart – MS Diagnostics by Country Figure 19 Chart – Rapid, POC and Other Diagnostics by Country